Novartis Ag

Andrew Dunstan

Catherine Howsham

Gurdip Bhalay

Thomas Anthony Hunt

Stephen Paul Collingwood

Lee Edwards

Nichola Smith

Peter Hunt

Emma Budd

Paul Joseph Oakley

Graham Charles Bloomfield

Peter Gedeck

Ian Bruce

Clive McCarthy

Thomas Ullrich

Amarylla Horvath

Trevor John Howe

Angela Glen

Paul Oakley

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R, R, Ar', A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

Organic compounds

Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel

Compounds of formula I in free or salt form, wherein T, X, Y, U, R, R, m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrrolidine derivatives acting as CCR3-receptor antagonists

Growing community of inventors

Horsham, United Kingdom

Andrew Dunstan